While the impacts of WHM and CMB on broader AD-related neurodegeneration and amyloid or tau pathology may be less pronounced, LI appears to exert a more localized effect on cognitive function without significantly affecting global brain atrophy or AD-specific biomarkers. The gene discussed is MAPT; the disease is Brain atrophy.